The next wave of metabolic medicines in development involves obesity drugs that offer the benefits of currently available injectable drugs in pill form. Corxel Pharmaceuticals has acquired the Phase 2-ready drug candidate, VCT220, a small molecule GLP-1 agonist developed by Vincentage Pharma. GLP-1 drugs mimic hormones to regulate blood sugar and suppress appetite, targeting the gut receptor also hit by other drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. Corxel plans to evaluate the drug, now known as CX11, in its own Phase 2 clinical trial for obesity. The company’s pipeline also includes other assets for acute ischemic stroke and hypertension.
Source link
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
